Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Venous Thrombosis 1Venous Thromboembolism 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Liver Diseases 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Oxaliplatin 30Gemcitabine 28Fluorouracil 27Capecitabine 22Leucovorin 19pembrolizumab 15130-nm albumin-bound paclitaxel 13Irinotecan 12Cisplatin 11Bevacizumab 11Albumin-Bound Paclitaxel 11Paclitaxel 10Ramucirumab 8Radiotherapy 8Docetaxel 8Nivolumab 7trastuzumab deruxtecan 6Cyclophosphamide 6Taxes 5Drug Therapy 5durvalumab 4Trastuzumab 4Metformin 4zolbetuximab 3spartalizumab 3folfirinox 3cemiplimab 3XELOX 3Surgical Procedures, Operative 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × Nadroparin × Gastrointestinal × Clear all
NCT00827554 2016-04-01

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

Eastern Hepatobiliary Surgery Hospital

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡